Sitemap Contact Imprint

Publications 2006 (IKP + RBK)

  • Alscher, DM, Mürdter, TE, Knabbe, C, Kuhlmann, U, Dippon, J, Hoffman, JE, Lage C: Creatinine measurements by the Jaffe method in different peritoneal dialysis fluids exhibit wide variation. Perit Dial Int 2006;26:280-3
  • Becquemont L, Glaeser H, Drescher S, Hitzl M, Simon N, Mürdter TE, Heinkele G, Hofmann U, Schaefer C, Burk O, Vestuyft C, Eichelbaum M, Fromm MF: Effects of ursodexycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans. Clin Pharmacol Ther 2006;79: 449-60
  • Beisner J, Buck MB, Fritz P, Dippon J, Schwab M, Brauch H, Zugmaier G, Pfizenmaier K, Knabbe C: A novel functional polymorphism in the transforming growth factor-beta2 gene promoter and tumor progression in breast cancer. Cancer Res 2006;66:7554-61
  • Bergheim I, Harsch S, Mueller O, Schimmel S, Fritz P, Stange EF: Apical sodium bile acid transporter and ileal lipid binding protein in gallstone carriers. J Lipid Res 2006;47(1):42-50
  • Betticher D, Martinelli G, Radford J, Kaufmann M, Dyer M, Kaiser U, Aulitzky W, Beck J, von Rohr A, Kovascovics T, Cogliatti S, Cina S, Maibach R, Cerny T, Linch D: Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: results of the international randomized phase III trial. Ann Oncol 2006;17(10):1546-52
  • Busse D, Templin S, Mikus G, Schwab M, Hofmann U, Eichelbaum M, Kivisto KT. Cardiovascular effects of (R)- and (S)-verapamil and racemic verapamil in humans: a placebo-controlled study. Eur J Clin Pharmacol 2006;62:613-619 (2006)
  • Fellermann K, Stange DE, Schaeffeler E, Schmalzl H, Wehkamp J, Bevins CL, Reinisch W, Teml A, Schwab M, Lichter P, Radlwimmer B, Stange EF: A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet 2006:79(3):439-48
  • Foster DJR, Morton EB, Heinkele G, Mürdter TE, Somogyi AA: Stereoselective quantification of methadone and a d6-labelled isotopomer using high performance liquid chromatography-atmospheric pressure chemical ionization mass-spectrometry: Application to a pharmacokinetic study in a methadone maintained subject. Ther Drug Monit 2006;28(4): 559-67
  • Frey A, Lampert A, Waldegger S, Jeck N, Waldegger P, Artunc F, Seebohm G, Lang UE, Kupka S, Pfister M, Hoppe J, Gerloff C, Schaeffeler E, Schwab M, Lang F: Influence of gain of function epithelial chloride channel ClC-Kb mutation on hearing thresholds. Hear Res 2006;214:68-75
  • Haas S, Pierl C, Harth V, Pesch B, Rabstein S, Ko Y, Hamann U, Justenhoven C, Brüning T, Brauch H, Fischer HP: Expression of xenobiotic and steroid hormone metabolizing enzymes in human breast carcinomas Internat. J Cancer 2006;119:1785-91
  • Hedman M, Antikainen M, Holmberg C, Neuvonen M, Eichelbaum M, Kivistö KT, Neuvonen PJ, Niemi M: Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardicac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. Br J Clin Pharmacol 2006;61:706-15
  • Herrlinger K, Witthoeft T, Raedler A, Bokemeyer B, Krummenerl T, Schulzke JD, Boerner N, Kueppers B, Emmrich J, Mescheder A, Schwertschlag U, Shapiro M, Stange EF: Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease. Am J Gastroenterol 2006;101(4):793-7
  • Hofmann U, Schwab M, Treiber G, Klotz U: Sensitive quantification of omeprazole and its metabolites in human plasma by liquid chromatography – mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2006:831-85-90
  • Igel M, Arnold KA, Niemi M, Hofmann U, Schwab M, Lütjohann D, von Bergmann K, Eichelbaum M, Kivistö KT: Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin Pharmacol Ther 2006;79:419-426
  • Karlstrom O, Stahle L, Perrin L, Tegude H, Sonnerborg A: Efficacy of nelfinavir-based treatment in the central nervous system of HIV-1 infected patients. Scand J Infect Dis 2006;38: 371-4
  • Kimmel M, Mark Alscher D, Dunst R, Braun N, Machleidt C, Kiefer T, Stulten C, van der Kuip H, Pauli-Magnus C, Raub U, Kuhlmann U, Mettang T: The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients. Nephrol Dial Transplant 2006;21(3):749-55
  • Klass DM, Buhrmann K, Sauter G, Del Puppo M, Scheibner J, Fuchs M, Stange EF. Biliary lipids, cholesterol and bile synthesis: different adaptive mechanisms to dietary cholesterol in lean and obese subjects. Aliment Pharmacol Ther 2006;23(7):895-905
  • Klingmuller U, Bauer A, Bohl S, Nickel PJ, Breitkopf K, Dooley S, Zellmer S, Kern C, Merfort I, Sparna T, Donauer J, Walz G, Geyer M, Kreutz C, Hermes M, Gotschel F, Hecht A, Walter D, Egger L, Neubert K, Borner C, Brulport M, Schormann W, Sauer C, Baumann F, Preiss R, MacNelly S, Godoy P, Wiercinska E, Ciuclan L, Edelmann J, Zeilinger K, Heinrich M, Zanger UM, Gebhardt R, Maiwald T, Heinrich R, Timmer J, von Weizsacker F, Hengstler JG: Primary mouse hepatocytes for systems biology approaches: a standardized in vitro system for modelling of signal transduction pathways. Syst Biol (Stevenage) 2006;153:433-47
  • Loboz KK, Gross AS, Williams KM, Liauw WS, Day RO, Blievernicht JK, Zanger UM, McLachlan AJ: Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clin Pharmacol Ther 2006;80(1):75-84
  • Lötsch J, Skarke C, Schmidt H, Rohrbacher M, Hofmann U, Schwab M, Geisslinger G: Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites. Clin Pharmacol Ther 2006;79:35-48
  • Meier Y, Pauli-Magnus C, Zanger UM, Klein K, Nüssler AK, Nüsserl N, Eichelbaum M, Meier PJ, Stieger B: Interindividual variability of canalicular ATP-binding-cassette (ABC)-Transporter expression in human liver. Hepatology 2006;44: 62-74
  • Momoi K, Hofmann U, Schmid RD, Urlacher VB: Reconstitution of ß-carotene hydroxylase activity of thermostable CYP175A1 monooxygenase. Biochem Biophys Res Comm 2006;339: 331-336
  • Niemi M, Arnold KA, Backmann JT, Pasanan MK, Gödtel-Armbrust U, Wojnowski L, Zanger UM, Neuvonen PJ, Eichelbaum M, Kivistö KT, Lang T: Polymorphism in ABCC2 is associated with increased hepatic MRP2 expression and reduced plasma pravastatin concentrations. Pharmacogenet Genomics 2006;16: 801-8
  • Niemi M, Kivistö KT, Dicfalusy U, Bodin K, Bertilsson L, Fromm MF, Eichelbaum M: Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin. Pharmacogenet Genomics 2006;16: 565-568
  • Nuding S, Fellermann K, Wehkamp J, Mueller HA, Stange EF: A flow cytometric assay to monitor antimicrobial activity of defensins and cationic tissue extracts. J Microbiol Methods 2006;65:335-45
  • Oscarson M, Zanger UM, Rifki OF, Klein K, Eichelbaum M, Meyer UA. Transcriptional profiling of genes induced in the liver of patients chronically treated with carbamazepine. Clin Pharmacol Ther 2006;80:440-456
  • Reinisch W, Hommes DW, van Assche G, Colombel JF, Gendre JP, Oldenburg B, Teml A, Geboes K, Ding H, Zhang L, Tang M, Cheng M, Van Deventer SJH, Rutgeerts P, Pearce T: A dose escalating, placebo-controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon y antibody, in patients with moderate to severe Crohn’s disease. Gut 2006;55:1138-44
  • Rothfuss KS, Bode JC, Stange EF, Parlesak A: Urinary excretion of polyethylene glycol 3350 during colonoscopy preparation. Z Gastroenterol 2006;44(2):167-72
  • Schaeffeler E, Eichelbaum M, Reinisch W, Zanger UM, Schwab M: Three novel thiopurine S-methyltransferase allelic variants (TPMT*20, *21, *22) - association with decreased enzyme function. Hum Mutat 2006;27:976
  • Schauber J, Rieger D, Weiler F, Wehkamp J, Eck M, Fellermann K, Scheppach W, Gallo RL, Stange EF: Heterogeneous expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2006;18:615-21
  • Schirmer M, Toliat MR, Haberl M, Suk A, Kamdem LK, Klein K, Brockmöller J, Nurnberg P, Zanger UM, Wojnowski L: Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations. Pharmacogenet Genomics 2006;16(1):59-71
  • Schmidt C, Hofmann U, Kohlmuller D, Mürdter T, Zanger UM, Schwab M, Hoffmann GF: Comprehensive analysis of pyrimidine metabolism in 450 children with unspecific neurological symptoms using high-pressure liquid chromatography-electrospray ionization tandem mass spectrometry. J Inherit Metab Dis 2006;28:1109-22
  • Stuelten CH, Buck MB, Dippon J, Roberts AB, Fritz P, Knabbe C: Smad4-expression is decreased in breast cancer tissues: a retrospective study. BMC Cancer 2006;6:25
  • Taetz S, Baldes C, Mürdter TE, Kleideiter E, Piotrowska K, Bock U, Haltner-Ukomadu E, Mueller J, Huwer H, Schaefer UF, Klotz U, Lehr C-M: Biopharmaceutical characterization of the telomerase inhibitor BRACO19. Pharm Res 2006;23:1031-7
  • The Breast Cancer Association Consortium: Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. J Nat Cancer Inst 2006;98:1382-96
  • Toscano C, Klein K, Blievernicht J, Schaeffeler E, Saussele T, Raimundo S, Eichelbaum M, Schwab M, Zanger UM: Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events. Pharmacogenet Genomics 2006;16:755-66
  • Toscano C, Raimundo S, Klein K, Eichelbaum M, Schwab M, Zanger UM. A silent mutation (2939G>A, exon 6; CYP2D6*59) leading to impaired expression and function of CYP2D6. Pharmacogenet Genomics 2006;16:767-70
  • van der Kuip H, Mürdter TE, Sonnenberg M, McClellan M, Gutzeit S, Gerteis A, Simon W, Fritz P, Aulitzky WE. Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment. BMC Cancer 2006;6:86
  • Voss E, Wehkamp J, Wehkamp K, Stange EF, Schroder JM, Harder J: NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2. J Biol Chem 2006;281:2005-11
  • Wassmann B, Pfeifer H, Goekbuget N, Beelen DW, Beck J, Stelljes M, Bornhauser M, Reichle A, Perz J, Haas R, Ganser A, Schmid M, Kanz L, Lenz G, Kaufmann M, Binckebanck A, Bruck P, Reutzel R, Gschaidmeier H, Schwartz S, Hoelzer D, Ottmann OG: Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2006;108(5):1469-77
  • Wehkamp J, Chu H, Shen B, Feathers RW, Kays RJ, Lee SK, Bevins CL: Paneth cell antimicrobial peptides: Topographical distribution and quantification in human gastrointestinal tissues. FEBS Lett 2006;580:5344-5350
  • Xin H, Schwab M, Klotz U: Transport studies with 5-aminosalicylate. Eur J Clin Pharmacol 2006;62: 871-5
  • Alscher DM, Herrlinger K, Stange EF: Disturbances in volume and electrolytes with intestinal and kidney diseases. Internist (Berl). 2006;47(11):1110-1120
  • Buck, MB, Knabbe, C: TGF-ß-signaling in breast cancer. Ann N Y Acad Sci 2006;1089:19-126
  • de Boer NK, Reinisch W, Teml A, van Bodegraven AA, Schwab M, Lukas M, Ochsenkuhn T, Petritsch W, Knoflach P, Almer S, van der Merwe SW, Herrlinger KR, Seiderer J, Vogelsang H, Mulder CJ; Dutch 6-TG working group. 6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party. Digestion 2006;73:25-31
  • Eichelbaum M, Ingelmann-Sundberg M, Evans WE: Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006;57:119-37
  • Eichelbaum M, Schwab M: Pharmacogenomics. In: Ruckpaul K, Ganten D (eds.). Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine. Volume 2: M – Z. 1. Auflage. Berlin: Springer 2006;1393-7
  • El Desoky ES, Derendorf H, Klotz U: Variability in response to cardiovascular drugs. Curr Clin Pharmacol 2006;1:35-46
  • Herrlinger KR, Jewell DP: Review article: interactions between genotype and response to therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2006;24:1403-12
  • Herrlinger K, Stange EF: Immunsuppressive und biologische Therapie bei Morbus Crohn und Colitis ulcerosa. Der Bayrische Internist 2006;26:132-143
  • Herrlinger K, Stange EF: Therapie chronisch entzündlicher Darmerkrankungen – Starte of the art. Kompendium Gastroenterologie 2006;2:2-5
  • Klein HG, Funke H, Neumaier M, Langmann T, Knabbe C, Cullen P. Kriterien für den Einsatz von Einzelnukleotidpolymorphismen (SNPs) in der medizinischen Routinediagnostik: Erarbeitung technischer und diagnostischer Empfehlungen. J Lab Med 2006;30: 142-151
  • Klotz U: Mechanismen und klinische Bedeutung von Arzneimittelinteraktionen. Klinikarzt 2006;35: 312-316 (2006)
  • Klotz U: Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther 2006;44: 297-302
  • Klotz U: Transdermale therapeutische Systeme (TTS). Prävent Rehabil 2006;18: 53-56
  • Klotz U: Ziconotide – a novel neuron-specific calcium channel blocker fort he intrathecal treatment of severe chronic pain: a short review. Int J Clin Pharmacol Ther 2006;44: 478-83
  • Kuebler I, Stange EF, Fellermann K, Wehkamp J: Defensins: endogenous antibiotics as a central part of innate immunity. Dtsch Med Wochenschr 2006;131:1960-1964
  • Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 2006;12(30):4819-31
  • Rothfuss KS, Bode JC, Stange EF, Parlesak A: Urinary excretion of polyethylene glycol 3350 during colonoscopy preparation. Z Gastroenterol 2006;44:167-72
  • Schmid M, Herrlinger K, Stange EF: Diagnostik und Therapie chronisch-entzündlicher Darmerkrankungen. Der Gastroenterologe 2006;Band 1, Heft 2
  • Schmid M, Kübler I, Stange EF, Fellermann K, Wehkamp J: Defensinbarrieredefekte bei Morbus Crohn. Der Bayrische Internist 2006;26: 120-6
  • Seyberth HW, Schwab M: Besonderheiten der Arzneimitteltherapie im Kindesalter. In: Lemmer B, Brune K (eds.). Pharmakotherapie. Klinische Pharmakologie. 13. Auflage. Springer 2006;471-8
  • Stange EF, Travis SP, Vermeire S, Beglinger C, Kupcinkas L, Geboes K, Barakauskiene A, Villanacci V, Von Herbay A, Warren BF, Gasche C, Tilg H, Schreiber SW, Scholmerich J, Reinisch W; European Crohn's and Colitis Organisation: European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006;55(Suppl 1):i1-15
  • Stange EF: Review article: the effect of aminosalicylates and immunomodulation on cancer risk in inflammatory bowel disease. Aliment Pharmacol Ther 2006;24 (Suppl 3):64-7
  • Travis SP, Stange EF, Lemann M, Oresland T, Chowers Y, Forbes A, D'Haens G, Kitis G, Cortot A, Prantera C, Marteau P, Colombel JF, Gionchetti P, Bouhnik Y, Tiret E, Kroesen J, Starlinger M, Mortensen NJ; European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006;55(Suppl 1):i16-35
  • Wehkamp J, Stange EF: Paneth cells and the innate immune response. Curr Opin Gastroenterol 2006;22: 644-50
  • Wehkamp J, Stange EF: A new look at Crohn’s disease: breakdown of the mucosal antibacterial defense. Ann NY Acad Sci 2006;1072: 321-31
  • Wehkamp J: Mögliche Auswirkungen auf die Therapie – Defekte Defensinbarriere bei Morbus Crohn. Klinikarzt 2006;10: 407-13
  • Weile J, Knabbe C: Molekulare Diagnostik (1): Onkologie. MTA Dialog 2006;10: 744-47
  • Weile J, Knabbe C: Molekulare Diagnostik (2): Infektiologie. MTA Dialog 2006;11: 827-9
  • Weile J, Knabbe C: Molekulare Diagnostik (3): Pharmakogenetik. MTA Dialog 2006;12: 914-6
  • Herrlinger KR, Fellermann K, Stange EF: Tacrolimus--finally! Gut 2006;55(9):1224
  • Jeck N, Waldegger S, Wissinger B, Schwab M, Lang F: Response: ClC-Kb Mutation Revisited. Hypertension 2006;Jan 30
  • Klotz U: Eszopiclon (Lunesta®, Estorra®) vs. Zopiclon. Arzneiverordnungen in der Praxis 2006;33:15-16
  • Wehkamp J und StangeEF: Zu wenig Abwehr- nicht zu viel: Aber warum ist die Entzündung ausgerechnet im Darm? Dtsch. Med. Wochenschr 2006;131(21):1199
  • Weile J, Knabbe C: DNA-Chip basierte Erreger- und Resistenzdiagnostik. Eine neue Methode mit Chancen? Management & Krankenhaus 2006;5: 40
Habilitations
  • Herrlinger, Klaus 
    Neue Klinische Aspekte zur Diagnostik und der Therapie chronisch entzündlicher Darmerkrankungen; Venia legendi für das Fach Innere Medizin and der Universität Freiburg

PhD/MD Theses
  • Toscano, Claudia 
    Molecular analysis of mechanisms leading to CYP2D6 intermediate and ultrarapid metabolizer phenotypes.
    Fakultät Geo- und Biowissenschaften der Universität Stuttgart zur Erlangung der Würde eines Doktors der Naturwissenschaften (Dr. rer. nat)
  • Wehkamp von Meissner, Birte
    Das Problem E. coli Nissle 1917 induziert das humane beta Defensin-2 (HBD-2) in intestinalen Epithelzellen: Ein möglicher neuer Wirkmechanismus. Medizinische Universität Tübingen
  • Weile, Jan 
    Epidemiologic studies about antibiotic susceptibility and virulence factors in Pseudomonas aeruginosa using DNA-microarrays. Dissertation (Dr. rer. nat) am Dr. Margaret Fischer-Bosch-Institut für Klinische Pharmakologie, dem Robert-Bosch-Krankenhaus und dem Institut für Technische Biochemie der Universität Stuttgart

Diploma Theses
  • Antoniadou, Lydia 
    Pharmakogenetische Untersuchungen zur Therapieprädiktion bei der Tamoxifenbehandlung von Brustkrebs; Fakultät für Biologie, Eberhardt Karls Universität Tübingen
  • Fait, Jeanette 
    Untersuchungen zur Funktion und Expression der Spleißvariante CAR(SV2) des „constitutive androstane receptor“. Fakultät für Biologie der Universität Tübingen
  • Feidt, Diana 
    RNA-Interferenz in Hepatomazelllinien und primären humanen Hepatozyten – am Beispiel der NADPH Cytochrom P450 Oxidoreduktase. Masterthesis zur Erlangung des akademischen Grades. Fachberich Naturwissenschaftliche Technik der Hochschule für Angewandte Wissenschaften Hamburg
  • Weigel, Karin 
    Regulierung und Überexpression von YB-1. Institut für Zellbiologie und Immunologie, Universität Stuttgart.